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High blood pressure (BP) is common in acute stroke and is 
associated with poor outcome. Previous hospital-based trials testing 
the effects of BP lowering on functional outcome have been 
inconclusive. The PIL-FAST and RIGHT pilot trials confirmed the 
feasibility of performing single-centre ambulance-based stroke trials 
in the UK. In both RIGHT and a subgroup of patients recruited 
within 6 hours into the large ENOS trial, transdermal glyceryl 
trinitrate (GTN, a nitric oxide donor) lowered BP and reduced death 
or disability. Based on these results, the Rapid Intervention with 
Glyceryl trinitrate in Hypertensive Stroke Trial-2 (RIGHT-2) is 




Over 1250 Paramedics from 7 UK ambulance services serving over 
40 comprehensive or primary stroke care centres are screening, 
consenting, randomising and treating 1050 patients presenting 
within 4 hours of FAST-positive stroke and with systolic BP >120 
mmHg. Treatment comprises GTN or similar sham patch, and is 
continued in hospital for 3 days. The primary outcome is the 
modified Rankin Scale at day 90. Secondary outcomes include 
vascular events, disability, quality of life, mood and cognition. 




Recruitment commenced in October 2015. As of Friday 13th October 
2017, 767 patients have been recruited from seven ambulance 
trusts conveying patients into 46 active stroke centres. Experiences 
with the trial and baseline characteristics of the recruited patients-
to-date will be presented. 
 
